Sign Up to like & get
recommendations!
1
Published in 2019 at "Cell Proliferation"
DOI: 10.1111/cpr.12592
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI. Our study aimed to investigate…
read more here.
Keywords:
egfr tki;
promotes erlotinib;
erlotinib resistance;
resistance ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3142
Abstract: Lung cancer is the leading cause of cancer-related deaths in the world. Non-small cell lung cancer (NSCLC) accounts for ~85% of the cases. NSCLC patients frequently harbor causal gene mutations. Epidermal Growth Factor Receptor (EGFR),…
read more here.
Keywords:
erlotinib resistance;
resistance;
cancer;
cell ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancers"
DOI: 10.3390/cancers14184395
Abstract: Simple Summary This study investigated the relationship between erlotinib resistance and stemness in lung adenocarcinoma. NCAPG2 was identified as an erlotinib resistance gene and maintained the stemness of lung adenocarcinoma. Abstract Erlotinib is a highly…
read more here.
Keywords:
lung adenocarcinoma;
stemness;
resistance;
erlotinib resistance ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Theranostics"
DOI: 10.7150/thno.84874
Abstract: [This corrects the article DOI: 10.7150/thno.35729.].
read more here.
Keywords:
resistance via;
aldehyde dehydrogenase;
erlotinib resistance;
confers erlotinib ... See more keywords